The BC-CfE’s Committee for Drug Evaluation and Therapy has issued and continues to update guidelines regarding SARS-CoV-2 and Persons Living with HIV. Please click the link below to see these statements.
All samples submitted for Drug Resistance Testing will now be tested for susceptibility to Protease and Reverse Transcriptase Inhibitors (nRTIs, NNRTIs, PIs) and Integrase Inhibitors. Separate requests are still required for GP41 drug resistance testing (susceptibility to Fusion Inhibitors) and HIV Coreceptor tropism testing (susceptibility to CCR5 antagonists). Updated requisition forms are available here.
If you'd like to receive periodic email notification from the British Columbia Centre for Excellence in HIV/AIDS of educational and other various events, newsletters, recent publications, and other research activities, please click below to sign up for our mailing lists.
In the 30 years since its inception in 1992, the advancements made by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) have transformed HIV from a tragically fatal disease, to a chronic and manageable illness that is highly, and easily, preventable.
The Treatment as Prevention strategy involves the widespread offer of HIV testing and immediate offer and use of highly active antiretroviral therapy (HAART) to people living with HIV who are medically eligible and willing.
The BC-CfE is dedicated to improving the health of British Columbians with HIV through the development, ongoing monitoring and dissemination of comprehensive research and treatment programs for HIV and related diseases.
© Copyright BC Centre for Excellence in HIV/AIDS, St. Paul's Hospital
608–1081 Burrard Street, Vancouver, BC, Canada V6Z 1Y6
Tel: 604-806-8477 | Fax: 604-806-9044
info@bccfe.ca
(Please do not use this email address to send personal information or book an appointment. To book appointments or contact the H2H clinic, please call 604-416-1517 or fax: 604-564-4893. Do not send your or your client's personal information via email.)
Copyright © 2022, BC Centre for Excellence in HIV/AIDS
